ESSA Pharma down as partner stops enrollment in prostate cancer study

ESSA Pharma

31/10/2022 12:35

** Shares of ESSA Pharma  EPIX.O  down ~26% at $3.27 before
the bell 
    ** EPIX says partner Janssen Research and Development is
suspending enrollment of patients in early-stage study of co's
lead drug EPI-7386 in combination with other prostate cancer
drugs due to "operational recruitment challenges"  urn:newsml:reuters.com:*:nCNWNdSxLa
    ** Co, Janssen were testing EPI-7386 combinations as a
potential treatment for metastatic castrate-resistant prostate
cancer (mCRPC) resistant to standard-of-care treatment
    ** EPIX was collaborating with Janssen since January 2021,
under which Janssen was to conduct combination therapy trials 
    ** Co is in discussions with Janssen for supply of the other
prostate cancer drugs, abiraterone acetate and apalutamide, for
an ESSA-sponsored combination study 
    ** As of last close, EPIX down ~69% YTD 
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))